BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

610 related articles for article (PubMed ID: 31448229)

  • 1. The Global Landscape of EBV-Associated Tumors.
    Shannon-Lowe C; Rickinson A
    Front Oncol; 2019; 9():713. PubMed ID: 31448229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Knockout of Epstein-Barr virus BPLF1 retards B-cell transformation and lymphoma formation in humanized mice.
    Whitehurst CB; Li G; Montgomery SA; Montgomery ND; Su L; Pagano JS
    mBio; 2015 Oct; 6(5):e01574-15. PubMed ID: 26489865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epstein-Barr virus detection in non-Hodgkin's lymphoma of the oral cavity: an immunocytochemical and in situ hybridization study.
    Leong IT; Fernandes BJ; Mock D
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2001 Aug; 92(2):184-93. PubMed ID: 11505266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epstein-Barr virus (EBV)-associated epithelial and non-epithelial lesions of the oral cavity.
    Kikuchi K; Inoue H; Miyazaki Y; Ide F; Kojima M; Kusama K
    Jpn Dent Sci Rev; 2017 Aug; 53(3):95-109. PubMed ID: 28725300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epstein-Barr virus-associated lymphoproliferative disorders.
    Grywalska E; Markowicz J; Grabarczyk P; Pasiarski M; RoliƄski J
    Postepy Hig Med Dosw (Online); 2013 May; 67():481-90. PubMed ID: 23752600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic Epstein-Barr Virus-Positive T/NK Lymphoproliferative Diseases With
    Ishimura M; Eguchi K; Shiraishi A; Sonoda M; Azuma Y; Yamamoto H; Imadome KI; Ohga S
    Front Pediatr; 2019; 7():183. PubMed ID: 31231620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EBV-Positive Lymphoproliferations of B- T- and NK-Cell Derivation in Non-Immunocompromised Hosts.
    Dojcinov SD; Fend F; Quintanilla-Martinez L
    Pathogens; 2018 Mar; 7(1):. PubMed ID: 29518976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epstein- Barr Virus: Clinical and Epidemiological Revisits and Genetic Basis of Oncogenesis.
    Ali AS; Al-Shraim M; Al-Hakami AM; Jones IM
    Open Virol J; 2015; 9():7-28. PubMed ID: 26862355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current Trends and Alternative Scenarios in EBV Research.
    Minarovits J; Niller HH
    Methods Mol Biol; 2017; 1532():1-32. PubMed ID: 27873264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathological features and EBV infection status of lymphoma in children and adolescents in South China: a retrospective study of 662 cases.
    Qin C; Huang Y; Feng Y; Li M; Guo N; Rao H
    Diagn Pathol; 2018 Feb; 13(1):17. PubMed ID: 29482573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-infections, inflammation and oncogenesis: future directions for EBV research.
    Rickinson AB
    Semin Cancer Biol; 2014 Jun; 26():99-115. PubMed ID: 24751797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular signature of Epstein Barr virus-positive Burkitt lymphoma and post-transplant lymphoproliferative disorder suggest different roles for Epstein Barr virus.
    Navari M; Fuligni F; Laginestra MA; Etebari M; Ambrosio MR; Sapienza MR; Rossi M; De Falco G; Gibellini D; Tripodo C; Pileri SA; Leoncini L; Piccaluga PP
    Front Microbiol; 2014; 5():728. PubMed ID: 25566237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epstein-Barr virus: dermatologic associations and implications: part II. Associated lymphoproliferative disorders and solid tumors.
    Eminger LA; Hall LD; Hesterman KS; Heymann WR
    J Am Acad Dermatol; 2015 Jan; 72(1):21-34; quiz 35-6. PubMed ID: 25497918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epstein Barr Virus Associated B-Cell Lymphomas and Iatrogenic Lymphoproliferative Disorders.
    Crombie JL; LaCasce AS
    Front Oncol; 2019; 9():109. PubMed ID: 30899698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epstein-Barr virus-associated B-cell lymphoproliferative disorders and lymphomas: a review.
    Marques-Piubelli ML; Salas YI; Pachas C; Becker-Hecker R; Vega F; Miranda RN
    Pathology; 2020 Jan; 52(1):40-52. PubMed ID: 31706670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In situ hybridisation for Epstein-Barr virus as a differential diagnostic tool for T- and natural killer/T-cell lymphomas in non-immunocompromised patients.
    Chuang SS
    Pathology; 2014 Dec; 46(7):581-91. PubMed ID: 25393247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EBV and Lymphomagenesis.
    Sausen DG; Basith A; Muqeemuddin S
    Cancers (Basel); 2023 Apr; 15(7):. PubMed ID: 37046794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epstein-Barr virus latency: LMP2, a regulator or means for Epstein-Barr virus persistence?
    Longnecker R
    Adv Cancer Res; 2000; 79():175-200. PubMed ID: 10818681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three restricted forms of Epstein-Barr virus latency counteracting apoptosis in c-myc-expressing Burkitt lymphoma cells.
    Kelly GL; Milner AE; Baldwin GS; Bell AI; Rickinson AB
    Proc Natl Acad Sci U S A; 2006 Oct; 103(40):14935-40. PubMed ID: 17001014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Viral-Targeted Strategies Against EBV-Associated Lymphoproliferative Diseases.
    Hui KF; Yiu SPT; Tam KP; Chiang AKS
    Front Oncol; 2019; 9():81. PubMed ID: 30873380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.